文献速递艾滋病与性传播感染病毒性肝炎

TURQUOISE-I 1b:奥比他韦/帕利瑞韦/利托那韦联合达沙布韦及利巴韦林治疗HIV-1合并HCV感染(达芦那韦方案)

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
PubMed 文献 · J Infect Dis · 2017-01-01

结果全部患者获得SVR12,无因不良事件停药,HIV-1 RNA维持抑制。

要点

  • HCV GT1/HIV-1合并感染患者接受OBV/PTV/r+DSV+RBV 12周,SVR12达100%。
  • 与达芦那韦联用对达芦那韦AUC和Cmax影响极小,Ctrough略降低。
  • 治疗期间无患者HIV-1 RNA超过200 copies/mL,间歇性HIV-1病毒血症不常见。

核心结论

  • HCV GT1/HIV-1合并感染且接受含达芦那韦稳定ART的患者,接受OBV/PTV/r+DSV+RBV治疗12周获得100% SVR12,并维持HIV-1 RNA抑制。

研究设计与样本

  • 患者随机维持达芦那韦800mg每日一次或换用达芦那韦600mg每日两次,所有患者接受OBV/PTV/r+DSV+RBV治疗12周。

主要发现

  • 无不良事件导致停药。
  • 合用对达芦那韦最大观察血浆浓度和AUC影响极小;达芦那韦Ctrough在每日一次和每日两次方案中均略降低。
  • 治疗期间无患者血浆HIV-1 RNA超过200 copies/mL。

临床怎么用

  • 对于接受含达芦那韦稳定ART的HCV GT1/HIV-1合并感染患者,可考虑OBV/PTV/r+DSV+RBV 12周方案,无需因达芦那韦暴露变化而调整方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients. In healthy controls, coadministration of OBV/PTV/r + DSV + darunavir (DRV) lowered DRV trough concentration (Ctrough) levels. To assess the clinical significance of this change, TURQUOISE-I, Part 1b, evaluated the efficacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRV-containing antiretroviral therapy (ART). METHODS: Patients were HCV treatment-naive or interferon-experienced, had CD4+ lymphocyte count ≥200 cells/µL or ≥14%, and plasma HIV-1 RNA suppression on once-daily (QD) DRV-containing ART at screening. Patients were randomized to maintain DRV 800 mg QD or switch to twice-daily (BID) DRV 600 mg; all received OBV/PTV/r + DSV + RBV for 12 weeks. RESULTS: Twenty-two patients were enrolled and achieved SVR12. No adverse events led to discontinuation. Coadministration had minimal impact on DRV maximum observed plasma concentration and area under the curve; DRV Ctrough levels were slightly lower with DRV QD and BID. No patient experienced plasma HIV-1 RNA >200 copies/mL during treatment. CONCLUSIONS: HCV GT1/HIV-1 coinfected patients on stable DRV-containing ART achieved 100% SVR12 while maintaining plasma HIV-1 RNA suppression. Despite DRV exposure changes, episodes of intermittent HIV-1 viremia were infrequent.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wyles D, Saag M, Viani RM, et al. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. J Infect Dis. 2017. PMID: 28329334. doi:10.1093/infdis/jiw597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。